Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.023.282 |
Chemical and physical data | |
Formula | C20H23NS |
Molar mass | 309.47 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Metixene (brand names Methixart, CholinFall, Tremonil, Trest), also known as methixene, is an anticholinergic used as an antiparkinsonian agent. It has also been reported to induce incomplete autophagy and cell death in metastatic cancer and brain metastases.
See also
References
- Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- Morton IK, Hall JM (1999). "Metixene". Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Dordrecht: Springer Netherlands. p. 178. ISBN 978-94-011-4439-1.
- Fares, Jawad (2023). "Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases". Journal of Clinical Investigation. doi:10.1172/JCI161142. PMC 10721147. PMID 37847564. Retrieved 3 November 2023.
Antiparkinson agents (N04) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Dopaminergics |
| ||||||||||
Anticholinergics | |||||||||||
Others |
| ||||||||||
|
This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |